From probiotics to therapeutics: Another step forward?

Research output: Contribution to journalArticle

10 Scopus citations


Preclinical studies with probiotics continue to unravel mechanisms of cytoprotection and suggest that approaches utilizing microbial products as therapeutics in acute and chronic gastrointestinal disorders could be effective. However, clinical trials using these bacteria have thus far been inconsistent. In this issue of the JCI, Yan et al. describe a novel mechanism of cytoprotection by p40, a soluble product of Lactobacillus rhamnosus GG, mediated via EGFR. The efficacy of p40 in three models of chemically induced colitis indicates tremendous therapeutic potential, though this finding will need to be verified in human patients.

Original languageEnglish (US)
Pages (from-to)2149-2152
Number of pages4
JournalJournal of Clinical Investigation
Issue number6
Publication statusPublished - Jun 1 2011


ASJC Scopus subject areas

  • Medicine(all)

Cite this